Clinical Trial Update: A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD) [Phase 2]

View source ↗

Summary

A Phase 2 pilot trial of melphalan, bortezomib, thalidomide, and dexamethasone (MEL-VTD) for multiple myeloma has been withdrawn from the study listing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Melphalan (Melphalan)
• Thalidomide (thalidomide)

Snippet

Sponsor: University of Arkansas | Conditions: Multiple Myeloma | Phase 2 | Status: WITHDRAWN